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Abstract
Background: Hypersecretion of cytokines and serine proteinases has been observed in asthma.
Since protease-activated receptors (PARs) are receptors of several serine proteinases and airway
epithelial cells are a major source of cytokines, the influence of serine proteinases and PARs on
interleukin (IL)-8 secretion and gene expression in cultured A549 cells was examined.
Results: A549 cells express all four PARs at both protein and mRNA levels as assessed by flow
cytometry, immunofluorescence microscopy and reverse transcription polymerase chain reaction
(PCR). Thrombin, tryptase, elastase and trypsin induce a up to 8, 4.3, 4.4 and 5.1 fold increase in
IL-8 release from A549 cells, respectively following 16 h incubation period. The thrombin, elastase
and trypsin induced secretion of IL-8 can be abolished by their specific inhibitors. Agonist peptides
of PAR-1, PAR-2 and PAR-4 stimulate up to 15.6, 6.6 and 3.5 fold increase in IL-8 secretion,
respectively. Real time PCR shows that IL-8 mRNA is up-regulated by the serine proteinases tested
and by agonist peptides of PAR-1 and PAR-2.
Conclusion: The proteinases, possibly through activation of PARs can stimulate IL-8 release from
A549 cells, suggesting that they are likely to contribute to IL-8 related airway inflammatory
disorders in man.
Background
Respiratory epithelium acts as the first tissue to meet
inhaled pathogens and is capable of releasing inflamma-
tory mediators and cytokines in response. Respiratory epi-
thelial cells can synthesize and secrete a variety of
proinflammatory cytokines such as IL-8, IL-1, IL-6, granu-
locyte-macrophage colony stimulating factor (GM-CSF)
[1] and RANTES [2] which regulate cell behavior includ-
ing growth, secretion, migration in physiological and
pathological conditions.
The importance of serine proteinases in the development
of airway diseases has been emphasized in recent years. Of
particular importance is that the potential role of tryptase
[3] thrombin [4] and elastase [5] in the development of
asthma, in which these serine proteinases were not only
been over-secreted [4,6,7], but also found to play a role in
induction of cytokine hypersecretion in airways [8,9].
However, the potential mechanism, through which these
serine proteinases carry out their actions in respiratory
tract, remains unclear. Since increased level of IL-8 in the
airways reported to be closely correlated to asthma [10],
we investigated the effect of tryptase, thrombin, trypsin,
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and elastase on IL-8 secretion and gene expression in
A549 cells, a type II alveolar epithelial cell line from
human adenocarcinoma, in the present study.
In recent years, PARs have been identified as receptors for
serine proteinases. Among them, PAR-1 is a receptor of
thrombin and trypsin [11]; PAR-2 is a receptor of trypsin,
tryptase [12] and elastase [9]; PAR-3 [13] and PAR-4 [14]
are receptors of thrombin. Activation of PARs could pro-
foundly alter secretion ability of numerous cell types such
as histamine release from human mast cells [15], IL-6
release from airway epithelial cells [8], IL-1 release from
fibroblast [16], and IL-8 release from human oral epithe-
lial cells [17]. We therefore investigated the effect of the
agonists of all four types of PARs on IL-8 release from
A549 cells in the current study. Since expression of PARs
on A549 cells is crucial for the understanding of actions of
the serine proteinases tested, we also investigated the
expression PAR-1, PAR-2, PAR-3 and PAR-4 on A549 cells
with immunocytochemical techniques and reverse tran-
scription polymerase chain reaction (RT-PCR) in the
present study.
Results
Induction of IL-8 release by serine proteinases
Thrombin at concentrations of 1–10 U/ml provokes a
concentration dependent release of IL-8 from A549 cells
following 16 h incubation period. Approximately 8 fold
increase in IL-8 release is observed at 16 h following incu-
bation with 10 U/ml thrombin (Figure 1A). The time
course study shows that increased release of IL-8 induced
by thrombin begins within 2 h, and lasts at least to 16 h
(Figure 1B).
At the concentrations from 1 to 300 ng/ml, trypsin is able
to stimulate a 'bell shape' release of IL-8 from A549 cells
following 16 h incubation period. The maximum release
of 5.1 fold is observed when 3 ng/ml of trypsin was added
to A549 cells. At the time of 8 h, however, a dose depend-
ent release of IL-8 from A549 cells is achieved with 100
and 300 ng/ml trypsin. Small but nevertheless significant
release of IL-8 is also observed with 300 ng/ml trypsin fol-
lowing 2 h incubation (Figure 2). Also in Figure 2, it is
clearly observed that the basal accumulated secretion of
IL-8 from A549 cells is time dependent with 2.7 ± 0.7, 173
± 54 and 329 ± 91 pg/ml being secreted following 2, 8 and
16 h incubation periods, respectively. Trypsin at concen-
tration of 300 ng/ml fails to stimulate IL-10, IL-16, IL-17
and IL-18 secretion from A549 cells following 8 h incuba-
tion period (data not shown).
Tryptase at the concentrations from 0.125 to 2 µg/ml
induces a concentration dependent IL-8 secretion from
A549 cells. Approximately 4.3 fold increase in release of
IL-8 is observed when 2 µg/ml of tryptase was incubated
with cells for 16 h, and as little as 0.25 µg/ml tryptase is
able to provoke a significant release of IL-8 from A549 cell
at 16 h following incubation (Figure 3A). Time course
study reveals that increased release of IL-8 induced by
tryptase begins within 2 h, and lasts at least to 16 h (Figure
3B). Elastase, however, only at the concentrations of 0.1
and 0.3 µg/ml elicits significant release of IL-8 following
16 h incubation period, and the quantity of IL-8 released
from A549 cells in response to 0.3 µg/ml elastase is simi-
lar to that induced by 2 µg/ml of tryptase (Figure 3A).
Time course study shows that elastase induced release of
IL-8 occurs after 8 h incubation and maintains at least to
16 h (Figure 3B).
Effect of thrombin on the release of IL-8 from A549 cells Figure 1
Effect of thrombin on the release of IL-8 from A549 cells. 
Cells were incubated (A) with various concentrations of 
thrombin at 37°C for 16 h, or (B) with 10 U/ml of thrombin 
for 2 h, 8 h and 16 h. Values shown are mean ± SE for 5 sep-
arate experiments. *P < 0.05 compared with the response to 
medium alone control.BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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Inhibition of IL-8 release induced by proteinases by their 
inhibitors
Hirudin, a specific thrombin inhibitor is able to inhibit
thrombin-induced secretion of IL-8 at both 2 and 16 h fol-
lowing incubation. The maximum inhibition of approxi-
mately 89% is observed when 10 U/ml of hirudin was
added to cells for 16 h (Table 2). Similarly, specific trypsin
inhibitors SBTI and α1-antitrysin are able to completely
abolish trypsin-induced secretion of IL-8 at both 8 and 16
h following incubation (Table 3). It is observed also that
MSACK, an inhibitor of elastase completely abrogates
elastase induced release of IL-8 (Table 4). In contrast,
inhibitors of tryptase, benzamine and leupeptine are only
able to inhibit tryptase induced IL-8 secretion by 47.5%
and 6.5%, respectively following 16 h incubation (Table
4). Hirudin (Table 2), SBTI, and α1-antitrysin (Table 3),
benzamidine, leupeptine and MSACK (Table 4) alone at
the concentrations tested have little effect on IL-8 secre-
tion from A549 cells.
Expression of PARs by A549 cells
FACS analysis shows that A549 cells express all four PARs
regardless they are permeabilized or not (Figure 4A).
Immunofluorescent cell staining shows that PAR-2 seems
mainly stained on the membrane surface of A549 cells,
whereas PAR-1, PAR-3 and particularly PAR-4 predomi-
nately stained in cytoplasm (Figure 4B). An agarose gel
electrophoresis revealed that A549 cells express mRNAs
for all four PARs (Figure 4C). The amplified RT-PCR prod-
ucts of PAR-1, PAR-2, PAR-3 and PAR-4 mRNAs were
sequenced and they all correspond to published
sequences of PAR genes (data not shown).
Induction of IL-8 release by agonists of PARs
SFLLR-NH2, a specific PAR-1 agonist peptide stimulats a
concentration dependent secretion of IL-8 from A549
cells following 16 h incubation (Figure 5A), whereas its
reverse peptide RLLFS-NH2 has no effect on IL-8 release.
The maximum release of IL-8 is 15.6 fold induced by 300
Effect of trypsin on the release of IL-8 from A549 cells Figure 2
Effect of trypsin on the release of IL-8 from A549 cells. Cells were incubated with various concentrations of trypsin at 37°C for 
2 h, 8 h or 16 h. Values shown are mean ± SE for 5 separate experiments. *P < 0.05 compared with the response to medium 
alone control.BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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µM of SFLLR-NH2 following 16 h incubation period (Fig-
ure 5A). However, TFRGAP-NH2, an agonist peptide of
PAR-3 and its reverse peptide PAGRFT-NH2 at concentra-
tions 0.1, 1, 10 and 100 µM do not show any influence on
IL-8 release from A549 cells following 16 h incubation
period (data not shown). The time course study shows
that SFLLR-NH2 induced release of IL-8 occurs after 8 h
incubation and sustains at least until 16 h (Figure 5B).
While SLIGKV-NH2 and tc-LIGRLO-NH2, two specific ago-
nists of PAR-2 induce concentration dependent secretion
of IL-8 from A549 cells following 8 and 16 h incubation
periods (Figure 6B,6C) only tc-LIGRLO-NH2 is able to
stimulate IL-8 release at 2 h (Figure 6A). The maximum
release of IL-8 is approximately 79 and 6.6 fold over base-
line induced by 100 µM of tc-LIGRLO-NH2 at 2 h and 100
µM of SLIGKV-NH2 at 8 h, respectively. VKGILS-NH2 has
little effect on IL-8 release, but tc-OLRGIL-NH2 appears to
induce a significant release IL-8 from A549 cells. How-
ever, the extent of release of IL-8 induced by tc-OLRGIL-
NH2 is much less than that induced by tc-LIGRLO-NH2
(Figure 6). SLIGKV-NH2 and tc-LIGRLO-NH2 at concen-
tration of 10 µM fail to stimulate IL-10, IL-16, IL-17, and
IL-18 secretion from A549 cells following 8 h incubation
period (data not shown).
At a concentration of 10 µM, GYPGQV-NH2, an agonist
peptide of PAR-4 induces a 3.5 fold increase in IL-8 release
from A549 cells. However, at a higher concentration (100
µM), it stimulates less IL-8 secretion (Figure 7A). VQG-
PYG-NH2, a reverse peptide of GYPGQV-NH2, at the con-
centrations tested does not show any influence on IL-8
release (Figure 7A). The time course study shows that
GYPGQV-NH2 induced release of IL-8 occurs after 8 h
incubation and sustains at least until 16 h (Figure 7B).
Effect of serine proteinases and agonists of PARs on 
expression of IL-8 mRNA in A549 cells
Thrombin, trypsin, tryptase and elastase stimulate an
increase in expression of IL-8 mRNA in A549 cells when
they were incubated with the cells. However, the tryptase
induced up-regulation of expression of IL-8 mRNA only
lasts for 2 h, whereas thrombin, trypsin (declined after 8
h) and elastase provoked expression of IL-8 mRNA con-
tinues until 16 h. Up to 6.8, 22.3, 9.9 and 7.8 fold increase
in expression of IL-8 mRNA is observed with thrombin,
trypsin, tryptase and elastase, respectively following incu-
bation with A549 cells (Figure 8). Dramatically enhanced
expression of IL-8 mRNA is found when SFLLR-NH2,
SLIGKV-NH2 or tc-LIGRLO-NH2 was incubated with A549
cells for 2 h. At 8 and 16 h following incubation, however,
IL-8 mRNA expression induced by SFLLR-NH2, SLIGKV-
NH2 or tc-LIGRLO-NH2 is greatly decreased (Figure 8).
GYPGQV-NH2  and TFRGAP-NH2  at 100 µM has little
influence on IL-8 mRNA expression in A549 cells (Figure
8). At the concentration of 100 µM, RLLFS-NH2, VKGILS-
NH2, tc-OLRGIL-NH2, PAGRFT-NH2 and VQGPYG-NH2,
the reverse peptides of agonists of PARs have little effect
on IL-8 mRNA expression in A549 cells (data not shown).
Discussion
It is demonstrated that human serine proteinases includ-
ing thrombin, tryptase, elastase and trypsin are potent
stimuli of IL-8 secretion from A549 cells, which suggests
that they are likely to play a role in IL-8 related airway
inflammatory disorders such as asthma, chronic obstruc-
tive pulmonary disease and cystic fibrosis.
As little as 5.6 nM of thrombin is able to stimulate approx-
imately 2 fold increase in IL-8 secretion, and 56 nM of
thrombin induces 8 fold increase in IL-8 release, indicat-
ing that this proteinase is a potent secretagogue of IL-8
release from A549 cells. Human mast cell tryptase, an
established mediator of inflammation [18] at a concentra-
tion as low as 3.7 nM induces twice more IL-8 secretion
over baseline release, and trypsin, a potential mediator of
airway inflammation [19] at a concentration of 0.042 nM
provokes approximately 3 fold increase in IL-8 secretion
from A549 cells, suggesting that tryptic enzyme in airways
may play a role in stimulation of IL-8 hypersecretion from
airway epithelium. Similarly, elastase, a well-established
mediator of airway inflammation at a concentration of
10.2 nM elicits 4.4-fold increase in IL-8 release, indicating
that it is a potent secretagogue of IL-8 release from A549
cells as well. At a concentration of 345 nM, elastase was
also found to be able to induce IL-8 and MCP-1 secretion
from human gingival fibroblasts [9]. However, at the con-
centrations higher than 62.5 nM elastase could disarm
PAR-2 within 10 min following incubation with human
lung epithelial cells [20]. These findings suggest that
elastase at lower concentrations induce cytokine release
from A549 cells, but at higher concentrations may inacti-
vate PAR-2 on human lung epithelial cells including A549
cells. It was impossible for us to examine the effect of
elastase at the concentrations higher than 62.5 nM with
our experimental system as at the concentration of 0.6 µg/
ml (20.4 nM), elastase was able to dissociate A549 cells
from plate after 8 h incubation and the suspended cells
died soon after (assessed by trypan blue staining). This
phenomenon may explain the reason for which elastase at
the concentration of 0.6 µg/ml fails to enhance IL-8
release. The similar phenomenon is also observed with
trypsin at the concentrations higher than 1 µg/ml. These
findings implicate that the detachment of bronchial epi-
thelium observed in chronic airway inflammation may
result from the hydrolytic activities of elastase and trypsin.
Time course study shows that IL-8 release induced by
thrombin, tryptase and trypsin initiates within 2 h follow-
ing incubation, whereas the response to elastase occurs
only after 8 h incubation period. This indicates thatBMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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elastase and the other proteinases tested may adopt differ-
ent mechanisms in induction of IL-8 release from A549
cells. The concentrations of tryptase and elastase used in
the present study should be achievable under pathological
conditions as the level of tryptase in asthmatic bronchial
alveolar lavage fluid was 13.2 ng/ml [21] and the levels of
elastase in asthmatic and cystic fibrosis sputum were 27
and 466 ng/ml, respectively [22]. While information on
the levels of thrombin and trypsin in respiratory fluids are
not available, a report described that trypsin-like activity
was 46.9 mU/ml in mucoid sputum from patients with
asthma [23] might implicate that the concentrations of
thrombin and trypsin used in the current study ought to
be achievable in the inflammatory airways.
A549 cells have been reported to secrete some 10 pg/ml of
elafin and 3 ng/ml of secretory leukocyte protease inhibi-
tor (SLPI) following 24 h incubation [24]. This concentra-
tion of elafin, an inhibitor of elastase should not affect the
action of elastase on A549 cells, but the concentrations of
SLPI, an inhibitor of trypsin and elastase may reduce the
stimulatory action of the lower concentrations of trypsin
or elastase on A549 cells.
Hirudin inhibites approximately 87% thrombin induced
IL-8 secretion; SBTI and α1-antitrypsin completely abolish
trypsin induced IL-8 secretion and MSACK eliminats 97%
elastase induced IL-8 secretion, suggesting strongly that
Table 2: Effect of hirudin on IL-8 release from A549 cells induced 
by thrombin
Compound (U/ml) IL-8 released (pg/ml)
2 h 16 h
Medium alone 18.7 ± 1.6 64.8 ± 7.2
Thrombin 3 40.1 ± 11.1 181 ± 32
Hirudin 3 18.4 ± 1.7 52.8 ± 5.7
Thrombin 3 + Hirudin 3 21.9 ± 7.2* 73.9 ± 12.9*
Thrombin 10 65.3 ± 18.4 478 ± 131
Hirudin 10 18.9 ± 2.1 59.3 ± 12.6
Thrombin 10 + Hirudin 10 26.8 ± 6.7* 119 ± 16.6*
Data shown are mean ± SE for five separate experiments. Thrombin, 
hirudin, and thrombin with hirudin were added to cells for 2 h or 16 
h. *P < 0.05 compared with the corresponding concentration of 
thrombin alone.
Table 1: Primer sequences for PARs
Primer Sequence Size of product (bp)
PAR-1 sense 5'-CAGCTCCTGGCTGACACTCTTTGTC-3' 500
antisense 5'-CGAGCAGGGTTTCATTGAGCACAT-3'
PAR-2 sense 5'-GCAGCCTCTCTCTCCTGCAGTGG-3' 461
antisense 5'-CTGAGGCAGGTCATGAAGAGAATGG-3'
PAR-3 sense 5'-GGCTGGACAGGAGCCACGAT-3' 403
antisense 5'-AGCGGTTGATGCTGATGCAGG-3'
PAR-4 RT 5'-TGAGTAGCTGGGATTACAG-3' 542
sense 5'-AACCTCTATGGTGCCTACGTGC-3'
antisense 5'- CCAAGCCCAGCTAATTTTTG-3'
β-actin sense 5'-GTTGCGTTACACCCTTTCTT-3' 148
antisense 5'-ACCTTCACCGTTCCAGTTT-3'
Effect of tryptase and elastase on the release of IL-8 from  A549 cells Figure 3
Effect of tryptase and elastase on the release of IL-8 from 
A549 cells. Cells were incubated with various concentrations 
of tryptase or elastase at 37°C for 16 h (A), or with 2 µg/ml 
tryptase or 0.3 µg/ml elastase for 2 h, 8 h and 16 h (B). Val-
ues shown are mean ± SE for 5 separate experiments. * P < 
0.05 compared with the response to medium alone control.BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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the actions of these proteinases on A549 cells are depend-
ent upon their intact catalytic sites. Since the known sub-
strates of these proteinases on cells are PARs, the
expression of PARs on A549 cells was investigated in the
present study. To our surprise, benzamidine and leupep-
tine at a concentration of 30 µg/ml (a quite high concen-
tration for the study on cells based on our previous work
[15] are only able to inhibit tryptase induced IL-8 secre-
tion by 47.5% and 6.5%, which suggests that IL-8 secre-
tion induced by tryptase may not depend on its enzymatic
activity, and there may be a receptor other than PARs
being involved in the process. The similar findings on
tryptase were observed previously in other studies [25].
However, to our knowledge, this is the first work examin-
ing the effects of thrombin, trypsin, tryptase and elastase
on IL-8 release from airway epithelial cells under the same
conditions.
It has been reported that a number of human cell types
express more than one member of PAR family. Thus,
platelets express PAR-1 and PAR-4 genes [14,26],
endothelial cells express PAR-1, PAR-2, and possibly PAR-
3 [13,27], fibroblast express PAR-1, PAR-2, PAR-3 and
PAR-4 genes [28], smooth muscle cell express PAR-1, PAR-
2, and PAR-3 genes [29] and respiratory epithelial cells
express PAR-1, PAR-2, PAR-3 and PAR-4 genes and possi-
bly proteins [8]. In the present study, we find that A549
cells express all four PARs at both protein and mRNA lev-
els. Since expression of the PARs was observed under both
permeabilized and non-permeabilized conditions, it is
most likely that all these four PARs are located in both the
cytoplasma and the plasma membrane surface of the cells.
The PAR family consists of a group of four G protein-cou-
pled receptors including PAR-1, PAR-2, PAR-3 and PAR-4.
They share a unique mechanism of activation involving
the proteolytic cleavage of the receptor by serine protein-
ases to unmask a new N-terminal sequence, the so-called
"tethered ligand" that autoactivates the receptor [30].
Thus, thrombin and trypsin cleavage PAR-1 within the
amino-tail (LDPR41↓S42FLLRN, where↓denotes cleavage),
trypsin, tryptase and elastase cleavages PAR-2 at the site of
SKGR34↓S35LIGKV, thrombin also cleavages PAR-3 at the
site LPIK38↓T39FRGAP and PAR-4 at PAPR47↓G48YPGQV
[31]. Synthetic receptor-activating peptides corresponding
to the new amino termini of the cleaved receptors can also
activate PARs [11]. Thus, SFLLR-NH2 [11], SLIGKV-NH2
[32] and tc-LIGRLO-NH2  [33], TFRGAP-NH2  [34],
GYPGQV-NH2 [35] represented agonists of PAR-1, PAR-2,
PAR-3 and PAR-4, respectively in the current study. For
comparison, their reverse peptides were used as controls.
SFLLR-NH2, tc-LIGRLO-NH2, SLIGKV-NH2 and GYPGQV-
NH2 stimulates approximately 15.6, 79, 6.6, and 3.5 fold
increase in release of IL-8, implicating that there are
appropriate mechanisms to carry out IL-8 release process
in response to PAR-1, PAR-2 and PAR-4 activation in A549
cells. However, A549 cells do not show any response (in
terms of IL-8 release) to PAR-3 activation. Activation of
A549 cells to release IL-8 by agonists of PARs indicates
that the actions of thrombin, tryptase, elastase and trypsin
on A549 cells are most likely carried out through hydro-
lytic cleavage of N-termini of PARs. The time course shows
that the influence of agonists of PAR-1 and PAR-2 on
A549 cells initiates within 2 h following incubation, but
the action of agonist of PAR-4 on cells appears only after
8 h incubation. These observations suggest that the
actions of thrombin on A549 cells are mainly (if not all)
carried out through PAR-1, but not PAR-4, whereas the
influence of trypsin on cells is most likely through both
Table 4: Effect of the inhibitors of tryptase or elastase on 
tryptase or elastase induced release of IL-8 from A549 cells
Compound (µg/ml) IL-8 released (pg/ml)
Medium alone 24.6 ± 1.5
Tryptase 2.0 105.2 ± 5.3*
Elastase 0.3 108.4 ± 13.2*
Benzamidine 30 37.6 ± 4.4
Leupeptine 30 27.4 ± 5.6
MSACK 30 22.1 ± 4.3
Tryptase 2.0 + Benzamidine 30 66.9 ± 4.8†
Tryptase 2.0 + Leupeptin 30 100 ± 1.7
Elastase 0.3 + MSACK 30 26.9 ± 3.6†
Data shown are mean ± SE for five to six separate experiments. 
Stimulus, inhibitor, or stimulus with inhibitor was incubated with cells 
for 16 h. * P < 0.05 compared with the response to medium alone; †P 
< 0.05 compared with the corresponding stimulus alone.
Table 3: Effect of trypsin inhibitors on IL-8 release from A549 
cells induced by trypsin
Compound (µg/ml) IL-8 released (pg/ml)
8 h 16 h
Medium alone 173 ± 54 581 ± 91
SBTI 10 154 ± 47 631 ± 102
SBTI 30 194 ± 52 646 ± 100
α1-AT 10 nd 505 ± 105
Trypsin 0.1 294 ± 78 993 ± 185
Trypsin 0.1 + SBTI 10 176 ± 47* 567 ± 110*
Trypsin 0.1 + SBTI 30 173 ± 49* 590 ± 120*
Trypsin 0.1 + α1-AT 10 nd 556 ± 133*
Trypsin 0.3 718 ± 147 1061 ± 366
Trypsin 0.3 + SBTI 10 158 ± 45* 543 ± 122*
Trypsin 0.3 + SBTI 30 256 ± 67* 654 ± 141*
Trypsin 0.3 + α1-AT 10 nd 579 ± 131*
Data shown are mean ± SE for five separate experiments. Trypsin, 
inhibitor, and trypsin with inhibitor were added to cells for 8 h or 16 
h. * P < 0.05 compared with the corresponding concentration of 
trypsin alone. α1-AT = α1-antitrypsin, SBTI = soybean trypsin 
inhibitor, nd = not done.BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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PAR-1 and PAR-2. It is hard to understand the slower
response of cells to elastase and at least partially enzy-
matic activity independent actions of tryptase on A549
cells. These obviously require further investigation. Using
various concentrations of agonist peptides of PARs to
stimulate A549 cells may better reflect the actions of these
peptides on the cells, which reinforces the previous find-
ing [8].
Analysis of expression of PARs on A549 cells by flow cytometry (A), Immunofluorescent microscopy (B) and RT-PCR (C) Figure 4
Analysis of expression of PARs on A549 cells by flow cytometry (A), Immunofluorescent microscopy (B) and RT-PCR (C). For 
PAR-1 and PAR-2 labeling, cells were incubated with PE-conjugated mouse anti-human PAR-1 monoclonal antibody and FITC-
conjugated mouse anti-human PAR-2 monoclonal antibody for 30 min on ice. For PAR-3 and PAR-4 labeling, cells were incu-
bated with rabbit anti-human PAR-3 or PAR-4 polyclonal antibodies for 30 min on ice followed by addition of FITC-conjugated 
goat anti-rabbit polyclonal antibodies. To detect cytoplasmic PARs, A549 cells were permeabilized with 0.2% Triton X-100 for 
5 min at room temperature before analysis. Immunofluorescent microscopy was performed with a laser scanning confocal 
microscope. For RT-PCR analysis of expression of mRNAs of PARs in A549 cells, the gene products of PARs were separated 
in 1.5% agarose gels, stained with SYBR Green I Nucleic Acid Gel Stain and photographed under UV light. Lane1-6 represented 
DNA marker, PAR-1 (500 bp), PAR-2 (461 bp), PAR-3 (403 bp), PAR-4 (542 bp) and β-actin (148 bp), respectively.
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Up-regulation of expression of IL-8 gene in A549 cells by
thrombin, trypsin, tryptase, elastase, PAR-1 and PAR-2
agonist peptides indicates that IL-8 released from A549
cells induced by these stimuli is most likely being newly
generated, rather than pre-stored in the cells. The observa-
tion that relatively small quantity of IL-8 was released dur-
ing the first 2 h of incubation in response to the above
stimuli also supports our view. While the influence of
tryptase and trypsin on IL-8 gene expression does not
appear to have been studied previously, the report which
found elastase [36,37] and thrombin [38] up-regulated IL-
8 gene expression in human epithelial cells may support
our current findings. To our knowledge, this is the first
work examining IL-8 gene expression in response to sev-
eral serine proteinases in epithelial cells under the same
conditions. The parallel investigation of the actions of ser-
ine proteinases on A549 cells may contribute to easier
understanding of the role of these proteinases in regula-
tion of IL-8 gene expression. It is difficult to understand
the reason why GYPGQV-NH2 does not significantly up-
regulate IL-8 gene expression, but stimulates IL-8 release
from A549 cells at 16 h following incubation. It could be
that the significantly increased IL-8 gene expression occurs
between 8 and 16 h incubation period, but we did not
examine it.
Effect of PAR-2 agonist peptides tc-LIGRLO-NH2 and  SLIGKV-NH2 and their reverse peptides, tc-OLRGIL and  VKGILS-NH2 on IL-8 release from A549 cells Figure 6
Effect of PAR-2 agonist peptides tc-LIGRLO-NH2 and 
SLIGKV-NH2 and their reverse peptides, tc-OLRGIL and 
VKGILS-NH2 on IL-8 release from A549 cells. Cells were 
incubated with various concentrations of tc-LIGRLO-NH2 
(open triangle), tc-OLRGIL (open reverse triangle), SLIGKV-
NH2 (open circle) or VKGILS-NH2 (open square) at 37°C for 
(A) 2 h, (B) 8 h and (C) 16 h. Values shown are Mean ± SE 
for five separate experiments performed in duplicate. *P < 
0.05 compared with the response to medium alone control; 
†P < 0.05 compared with the response to the corresponding 
reverse peptide at the same concentration.
Effect of SFLLR-NH2, an agonist peptide of PAR-1 and its  reverse peptide RLLFS-NH2 on IL-8 release from A549 cells Figure 5
Effect of SFLLR-NH2, an agonist peptide of PAR-1 and its 
reverse peptide RLLFS-NH2 on IL-8 release from A549 cells. 
Cells were incubated (A) with various concentrations of 
SFLLR-NH2 (open bar) or RLLFS-NH2 (hatched bar) at 37°C 
for 16 h or (B) with 100 µM of SFLLR-NH2 and RLLFS-NH2 
for 2 h, 8 h and 16 h. Values shown are Mean ± SE for five 
separate experiments performed in duplicate. *P < 0.05 com-
pared with the response to medium alone control; †P < 0.05 
compared with the response to RLLFS-NH2 at the same con-
centration.
SFLLR-NH2
RLLFS-NH2
RLLFS-NH2
Medium alone
SFLLR-NH2BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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Induction of inflammatory mediator release from airway
epithelial cells by agonists of PARs has been demonstrated
previously. Thus, agonist of PAR-1 stimulated platelet-
derived growth factor secretion from lung epithelial cells
[39]; agonists of PAR-2 stimulated IL-8 secretion from 16
HBE cells [40], GM-CSF and eotaxin release from human
pulmonary epithelial cells [41] and matrix metalloprotei-
nase-9 release from A549 and primary cultured small air-
way epithelial cells [42], and agonist of PAR-4 stimulated
IL-8 secretion from human respiratory epithelial cells [8].
Our findings further strengthen the view that through acti-
vation of PARs, serine proteinases are actively involved in
the pathogenesis of airway inflammation.
However, since A549 cells is not a normal airway epithe-
lial cells, it may not fully represent the events happening
in normal airway epithelial cells in response to the stimuli
above in real life.
Conclusion
serine proteinases tested are potent stimuli of IL-8 secre-
tion from A549 cells, and the influence of these protein-
ases on airway epithelial cells are most likely through
activation of PARs. Induction of IL-8 secretion by protein-
ases indicates that they are likely to contribute to the
pathogenesis of airway inflammatory disorders.
Development of proteinase inhibitor drugs may be valua-
ble for treatment of these diseases.
Methods
Reagents
Human thrombin, trypsin, soybean trypsin inhibitor
(SBTI), α1-antitrypsin, leupeptin, benzamidine, parafor-
maldehyde and bovine serum albumin (BSA, fraction V)
were all Sigma products. Nonenzymatic cell dissociation
Effect of serine proteinases and agonist peptides of PARs on  the expression of IL-8 mRNA in A549 cells Figure 8
Effect of serine proteinases and agonist peptides of PARs on 
the expression of IL-8 mRNA in A549 cells. Total cellular 
RNA was isolated, reverse transcribed to cDNA, and the 
cDNA was used for real-time PCR. Cells were treated with 
the testing compounds at 37°C for 2 (open bars), 8 (left 
hatched bars) and 16 h (right hatched bars), respectively. The 
data were normalized to the housekeeping gene (β-actin 
gene) and were expressed as mean ± SE fold of control for 
three separate experiments performed in duplicate. *p < 
0.05 compared with the baseline control.
Effect of GYPGQV-NH2, a PAR-4 agonist peptide and its  reverse peptide VQGPYG-NH2 on release of IL-8 from A549  cells Figure 7
Effect of GYPGQV-NH2, a PAR-4 agonist peptide and its 
reverse peptide VQGPYG-NH2 on release of IL-8 from A549 
cells. Cells were incubated with various concentrations of 
GYPGQV-NH2 or VQGPYG-NH2 at 37°C for 16 h (A), or 
with 10 µM of GYPGQV-NH2 for 2 h, 8 h and 16 h (B). Val-
ues shown are mean ± SE for 5 separate experiments. *P < 
0.05 compared with the response to medium alone control; 
†P < 0.05 compared with the response to VQGPYG-NH2 at 
the same concentration.BMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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solution (CDS) was obtained from Sigma-Aldich (St
Louis, MO, USA). Recombinant hirudin, human neu-
trophil elastase and MeOSuc-Ala-Ala-Pro-Ala-CMK
(MSACK) were obtained from Calbiochem (San Diego,
CA, USA). Recombinant human Lung βtryptase was from
Promega (Madison, WI, USA). Agonist peptides of PARs,
as well as their reverse forms were synthesized (CL Bio-Sci-
entific Inc, Xi An, China). The sequences of the active and
control peptides, respectively, were: PAR-1, SFLLR-NH2
and RLLFS-NH2; PAR-2, SLIGKV-NH2 and VKGILS-NH2 as
well as trans-cinnamoyl (tc)-LIGRLO-NH2  and tc-
OLRGIL-NH2; PAR-3, TFRGAP-NH2  and PAGRFT-NH2;
PAR-4, GYPGQV-NH2 and VQGPYG-NH2. Tissue culture
reagents were purchased from GIBCO (Carlsbad, CA,
USA) and Sigma Inc. Human IL-8 ELISA kits were pur-
chased from R&D Systems (Minneapolis, MN). TRIzol
Reagent was from Invitrogen (Carlsbad, CA, USA). The
RNA-PCR kit was from TaKaRa (DaLian, China). SYBR
Green I Nucleic Acid Gel Stain was from BMA Inc (USA).
PE-conjugated mouse anti-human PAR-1 monoclonal
and FITC- conjugated mouse anti-human PAR-2 mono-
clonal antibodies, anti-PAR-3 and anti-PAR-4 rabbit poly-
clonal IgGs were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). FITC-conjugated
goat anti-rabbit polyclonal antibody was from BD
Pharmingen (San Jose, CA, USA). Platinum® SYBR® Green
qPCR kit and Superscript® First Strand System were from
invitrogen Corp. (Carlsbad, CA, USA). Most of other rea-
gents such as salt and buffer components were analytical
grade and obtained from Sigma (St. Louis, MO, USA). The
human lung carcinoma cell line A549 (Morphology: epi-
thelial) was obtained from the American Type Culture
Collection (Manassas, VA, USA).
Cell cultures
A549 cells were grown in Dulbecco's modified Eagle's
medium (DMEM), supplemented with 10% (v/v) fetal
calf serum (FCS), 100 U/ml penicillin and 100 µg/ml
streptomycin. Cells were cultured in 75-cm2 tissue culture
flasks (Falcon) at 37°C in a 5% (v/v) CO2, water-saturated
atmosphere.
Stimulation of epithelial cells
Cells were detached from culture flasks using trypsin,
seeded into 12-well tissue culture plates, and grown to
about 80% confluence. The cells were then cultured with
the serum-free basal medium for an additional 16 h
before challenge. For challenge experiments, cells were
exposed to various concentrations of thrombin (0.01 – 10
U/ml, 1 U/ml = 5.6 nM), trypsin (1 – 300 ng/ml, 1 µg/ml
= 42 nM), tryptase (0.125 – 2 µg/ml, 1 µg/ml = 7.4 nM),
elastase (0.01 – 0.6 µg/ml, 1 µg/ml = 34 nM) and their
peptidase inhibitors, respectively, and also to PAR-1, PAR-
2, PAR-3 and PAR-4 agonist peptides, as well as their
reverse peptides (0.1 – 100 µM), respectively. Culture
supernatants (1 ml per well) were collected at different
times (2 h, 8 h, 16 h), centrifuged at 4°C, and stored at -
80°C until use. Concentrations of IL-8 in the A549 culture
supernatants were quantified using commercial specific
ELISA kits according to the manufacturer's instructions.
Identification of expression of mRNA of PARs
The expression of mRNA of PARs by A549 cells was inves-
tigated with RT-PCR technique. Total RNA was isolated
using TRIzol reagent according to the manufacturer's
instructions. Briefly, cells were lysed directly by adding 1
ml of TRIzol Reagent to a 3.5 cm diameter dish (1 ml per
10 cm2). A total of 200 µl of chloroform was added, and
tubes were then centrifuged at 12,000 g for 15 min at 4°C,
after which the aqueous phase was transferred to new
tubes, RNA was precipitated by adding 0.5 ml of isopropyl
alcohol, and then centrifuged at 12,000 g for 10 min at
4°C. Finally, 1 ml of 75% (v/v) ethanol was added to the
pelleted RNA, and centrifuged at 7,500 g for 5 min at 4°C.
Total RNA was quantified by measuring absorbance ratios
at 260/280 nm. cDNA was prepared by reverse tran-
scriptase using a commercial RNA-PCR kit, and reactions
were performed according to the manufacturer's instruc-
tions. For each reaction, 1 µg of total RNA was reversely
transcribed using oligo-d (T) and PAR-4 RT primers
according to the protocol. The cDNA was amplified using
forward and reverse specific primers for amplifying
human PARs. β-actin was used as an internal control.
Primers for PAR-1, PAR-2 and PAR-3 were designed based
on PAR sequences in Genbank using Omiga software;
Primer for PAR-4 was designed as described by Kahn et al
[26]. Primers were prepared by Invitrogen Biotechnology
Co., Ltd. The primer sequences were summarized in Table
1. The conditions for amplification were: for PAR-1, PAR-
2, and PAR-3, the PCR mixture was heated at 94°C for 2
min followed by 35 cycles at 94°C for 30 sec, 67°C for 30
sec, 72°C for 1 min and 72°C for 10 min for 1 cycle; for
PAR-4 and β-actin, the PCR mixture was heated at 94°C
for 2 min followed by 35 cycles at 94°C for 30 sec, 55°C
for 30 sec, 72°C for 30 sec and 72°C for 10 min for 1
cycle. Electrophoresis was conducted in 1.5% agarose gels
that were stained with SYBR Green I Nucleic Acid Gel
Stain and photographed under UV light. PCR products
were then sequenced.
Quantitative real-time PCR
IL-8 mRNA expression in A549 cells was determined by
real-time PCR following the manufacture's protocol.
Briefly, total RNA was isolated from the stimulated A549
cells using TRIzol Reagent. cDNA was synthesized from 5
µg of total RNA by using Superscript first strand synthesis
system for RT-PCR and oligo-dT primers. A double-
stranded DNA binding dye method was used for quantita-
tive PCR/RT-PCR. Real-time PCR was performed in the
ABI Prism 7700 Sequence Detection System (Perkin ElmerBMC Cell Biology 2006, 7:22 http://www.biomedcentral.com/1471-2121/7/22
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Applied Systems, Foster City, CA, USA) using the Plati-
num SYBR Green I PCR kit [each reaction containing 12.5
µl of 2 × SYBR green Master Mix, 300 nM of primers
[43,44], 5 µl of a 1:10 dilution of the cDNA or plasmid
DNA and water to a total of 25 µl]. The thermal cycling
conditions included an initial denaturation step at 95°C
for 2 min, 40 cycles at 95°C for 15 s, 60°C for 30 s, and
72°C for 30 s. Consequently, at the end of the PCR cycles,
the real-time PCR products were immediately analyzed
using a ramping rate of 0.03°C/s from 60 to 95°C to cal-
culate the dissociation curve to verify the correctness of
the amplicons. None-template controls for each primer
pair were also included on each reaction plate to check for
external DNA contamination. Sequence-specific standard
curves were generated using 10-fold serial dilutions of
plasmid DNA (104~109 copies), and then the values for
the initial concentrations of unknown samples were cal-
culated by using the software (version 1.7) provided with
the ABI 7700 system. IL-8 mRNA expression in each sam-
ple was finally determined after correction with β-actin
expression. Each measurement of a sample was conducted
in duplicate.
Flow cytometry analysis
Adherent A549 cells were detached from culture flasks
using the cell dissociation solution. Cells were pelleted by
centrifugation, fixed with 2% paraformaldehyde, and
resuspended in 1% BSA/PBS. Cells were incubated
directly with 1 in 20 dilution of PE-conjugated mouse
anti-human PAR-1 monoclonal and FITC-conjugated
mouse anti-human PAR-2 monoclonal antibodies for 30
min on ice, followed by two washes with 1% BSA/PBS. For
PAR-3 and PAR-4 staining, cells were incubated with 1 in
20 dilution of rabbit polyclonal antibodies for a period of
30 min on ice. After two washes with 1% BSA/PBS,
immunofluorescence staining was performed with 1 in
100 dilution FITC-conjugated goat anti-rabbit polyclonal
antibodies for 30 min on ice. Finally, cells were resus-
pended in PBS and labeled cells were analyzed on a FACS
Calibur flow cytometer with the use of CellQuest software
(BD Biosciences). For staining cytoplasmic PARs, A549
cells were permeabilized with 0.2% Triton X-100 for 5
min at room temperature.
Immunofluorescence cell staining
A549 cells were seeded onto 8 chamber microscope slides
(Nalgene Nunc chamber slides) and allowed them to
adhere overnight. The cells were then washed with PBS
with 1% BSA followed by fixation in methanol for 20 min
on ice. After which the cells were incubated for 5 min with
the same wash buffer. Cells were stained directly with 1 in
20 dilution of PE-conjugated mouse anti-human PAR-1
and PAR-2 monoclonal antibodies for 1 h at room tem-
perature and followed by three 1 min washes with 1%
BSA/PBS. For PAR-3 and PAR-4 staining, cells were incu-
bated with 1 in 20 dilution of rabbit polyclonal IgG anti-
bodies for a period of 1 h at room temperature and
followed by three 1 min washes with 1% BSA/PBS. A
FITC-conjugated goat anti-rabbit polyclonal antibody was
then added for 1 h at room temperature and followed by
a further 1% BSA/PBS wash. Images were obtained on a
Nikon EZ-C1 confocal laser scanning microscope (Japan).
Determination of IL-8, IL-10, IL-16, IL-17 and IL-18
IL-8, IL-10, IL-16, IL-17 and IL-18 release was measured
by using ELISA kits according to the manufacturer's
instruction.
Statistics
Data are expressed as mean ± SEM for the indicated
number of independently performed duplicated experi-
ments. Statistical significance between means was ana-
lyzed by one-way ANOVA or the Student's t test utilizing
the SPSS11.0 version. P < 0.05 was taken as statistically
significant.
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